Patents Assigned to Niigata University
-
Patent number: 12291710Abstract: The present invention provides an antisense oligonucleotide that is formed of 15-22 nucleotides and that is complementary to a nucleic acid including at least 15 consecutive bases in a specific target region of a base sequence of SEQ ID NO: 471 (which encodes atrophin 1; ATN1), or a pharmaceutically acceptable salt thereof, or a hydrate thereof.Type: GrantFiled: June 12, 2024Date of Patent: May 6, 2025Assignees: Nippon Shinyaku Co., Ltd., Niigata UniversityInventors: Takao Kawano, Toshiaki Ode, Akie Chiba, Osamu Onodera, Taisuke Kato, Sachiko Hirokawa
-
Patent number: 12239621Abstract: One object of the present invention is to provide an inhibitor for renal injuries induced by a hemolytic reaction. In this invention, cilastatin or a pharmaceutically acceptable salt thereof is used.Type: GrantFiled: March 8, 2022Date of Patent: March 4, 2025Assignees: Niigata University, Denka Company LimitedInventors: Akihiko Saito, Sawako Goto, Yoshiaki Hirayama
-
Publication number: 20240299496Abstract: The present inventors have discovered that a peptide derived from HMGB1 can be used as a therapeutic and/or preventive agent for fatty liver, nonalcoholic steatohepatitis, and various symptoms accompanied by the fatty liver. On the basis of this discovery, the present application provides a use of the peptide derived from HMGB1 which is different from conventional uses.Type: ApplicationFiled: September 30, 2022Publication date: September 12, 2024Applicants: Osaka University, Niigata University, StemRIM Inc.Inventors: Katsuto TAMAI, Takashi SHIMBO, Shuji TERAI, Atsunori TSUCHIYA, Takehiko YAMAZAKI
-
Patent number: 11869190Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.Type: GrantFiled: April 4, 2022Date of Patent: January 9, 2024Assignees: Niigata University, Denka Company LimitedInventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
-
Patent number: 11858984Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.Type: GrantFiled: April 15, 2019Date of Patent: January 2, 2024Assignees: National University Corporation Okayama University, Niigata University, National University Corporation Gunma UniversityInventors: Masakiyo Sakaguchi, Shinichi Toyooka, Shuta Tomida, Kazuhiko Shien, Hiroki Sato, Rie Kinoshita, Junichiro Futami, Kota Araki, Mikio Okazaki, Eisaku Kondo, Yusuke Inoue, Akira Yamauchi
-
Publication number: 20230366890Abstract: The present invention provides a method of assisting a determination of whether a subject is susceptible to infection by norovirus or whether a subject is susceptible to post-infection worsening, wherein this method contains a step of measuring the concentration of IgG antibody that is present in a sample originating from within the oral cavity of the subject.Type: ApplicationFiled: October 7, 2021Publication date: November 16, 2023Applicants: Niigata University, Denka Company LimitedInventors: Akihiko SAITO, Michihiro HOSOJIMA, Hideyuki KABASAWA, Nobumasa AOKI, Kei NAGANO, Sakari SEKINE, Keisuke MUNEKATA
-
Publication number: 20220301167Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.Type: ApplicationFiled: April 4, 2022Publication date: September 22, 2022Applicants: Niigata University, Denka Company LimitedInventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
-
Patent number: 11414655Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily and efficiently obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein (1) a 4th amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, and (2) an amino acid adjacent to the N-terminus of a (A/S/G)RX(H/N)XXP motif is substituted with an amino acid other than tyrosine, or a 4th amino acid of the GXGX(G/A/P) motif is substituted with an amino acid other than leucine.Type: GrantFiled: August 31, 2018Date of Patent: August 16, 2022Assignees: Niigata University, Adeka CorporationInventors: Tsutomu Sato, Tsutomu Hoshino, Toshihiko Takehana, Seiji Koike, Koichi Shigeno
-
Patent number: 11295447Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.Type: GrantFiled: February 7, 2019Date of Patent: April 5, 2022Assignees: Niigata University, Denka Company LimitedInventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
-
Publication number: 20210163537Abstract: This peptide is composed of an amino acid sequence represented by general formula (I), and has a high degree of accumulation in cancer cells or cancer tissue in a digestive system. (In general formula (I), X11 is a peptide residue composed of an amino acid sequence of (a) or (b) below: (a) an amino acid sequence represented by any of SEQ ID NOs: 1 to 3, (b) an amino acid sequence including a sequence in which one or two amino acids have been deleted, substituted or added in an amino acid sequence represented by any of SEQ m NOs: 1 to 3; Y11 is a peptide linker composed of an amino acid residue of at least 1 but not more than 10 amino acids, wherein each amino acid residue is independently a glycine residue, a proline residue, a serine residue a cysteine residue or a lysine residue; X12 is either a peptide residue composed of an amino acid sequence of (a) or (b) above, or a retro-inverso peptide residue thereof; and n11 represents an integer of at least 1 but not more than 9.Type: ApplicationFiled: April 25, 2019Publication date: June 3, 2021Applicant: Niigata UniversityInventors: Eisaku KONDO, Ken SAITO
-
Publication number: 20210045195Abstract: An infrared radiation device includes a body including a heat generating part and first and second metamaterial structures that are capable of radiating infrared rays having a peak wavelength of a non-Planck distribution upon receipt of thermal energy from the heat generating part. The first metamaterial structure is disposed on a first surface side of the heat generating part, and the second metamaterial structure is disposed on a second surface side opposite to the first surface side of the heat generating part.Type: ApplicationFiled: October 19, 2020Publication date: February 11, 2021Applicants: NGK Insulators, Ltd., National University Corporation Hokkaido University, Niigata UniversityInventors: Michiro AOKI, Yoshio KONDO, Tsuyoshi TOTANI, Atsushi SAKURAI
-
Publication number: 20210035300Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.Type: ApplicationFiled: February 7, 2019Publication date: February 4, 2021Applicants: Niigata University, Denka Company LimitedInventors: Toshifumi Wakai, Shujiro Okuda, Yoshifumi Shimada, Hiroshi Izutsu, Keisuke Kodama
-
Publication number: 20200354754Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily and efficiently obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein (1) a 4th amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, and (2) an amino acid adjacent to the N-terminus of a (A/S/G)RX(H/N)XXP motif is substituted with an amino acid other than tyrosine, or a 4th amino acid of the GXGX(G/A/P) motif is substituted with an amino acid other than leucine.Type: ApplicationFiled: August 31, 2018Publication date: November 12, 2020Applicants: Niigata University, Adeka CorporationInventors: Tsutomu Sato, Tsutomu Hoshino, Toshihiko Takehana, Seiji Koike, Koichi Shigeno
-
Patent number: 10668125Abstract: Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.Type: GrantFiled: October 21, 2016Date of Patent: June 2, 2020Assignee: Niigata UniversityInventors: Eisaku Kondo, Ken Saito
-
Patent number: 10420741Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof.Type: GrantFiled: July 21, 2016Date of Patent: September 24, 2019Assignees: EA Pharma Co., Ltd., Niigata UniversityInventors: Akihiko Saito, Nobumasa Aoki, Yoshihisa Hori, Shoji Kuwahara, Michihiro Hosojima, Hiroshi Iwata, Saori Matsuda
-
Publication number: 20190246457Abstract: An infrared heater includes a heater body and a casing. The heater body includes a heating element and a metamaterial structure capable of emitting infrared radiation having a peak wavelength of a non-Planck distribution when thermal energy is supplied from the heating element. The casing has an interior space in which the heater body is disposed and whose pressure is reducible. In addition, the casing includes an infrared radiation transmitting portion capable of transmitting the infrared radiation emitted by the metamaterial structure to an outside of the casing.Type: ApplicationFiled: April 17, 2019Publication date: August 8, 2019Applicants: NGK INSULATORS, LTD., National University Corporation Hokkaido University, National University Corporation Niigata UniversityInventors: Michiro AOKI, Yoshio Kondo, Tsuyoshi Totani, Atsushi Sakurai
-
Publication number: 20190078120Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein a fourth amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, (a) having a QXXXGX(W/F) motif, and a QXXXX(G/A)X(F/W/Y) motif on the N-terminal side, and a QXXXGX(F/W/Y) motif, and a QXXXGXW motif and a QXXXGX(F/W) motif on the C-terminal side, and not having a QXXXGXW motif at a position separated by 170 amino acid residues or more on the C-terminal side, with respect to the DXDD motif, (b) having 40% or more identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 13, (c) exhibiting ambrein production activity using squalene as a substrate.Type: ApplicationFiled: March 3, 2017Publication date: March 14, 2019Applicants: Niigata University, Adeka CorporationInventors: Tsutomu SATO, Kotone OKUNO, Toshihiko TAKEHANA, Seiji KOIKE
-
Publication number: 20180360903Abstract: The present invention provides a novel peptide that acts directly on pancreatic cancer cells and tissues and has highly-shifted accumulation thereto. Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS:1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS:1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.Type: ApplicationFiled: October 21, 2016Publication date: December 20, 2018Applicant: Niigata UniversityInventors: Eisaku Kondo, Ken Saito
-
Publication number: 20180357930Abstract: Provided is a pseudo visceral model having a specific texture. A model of viscera, tissues, or organs comprising a foam layer containing a hydrogel.Type: ApplicationFiled: December 2, 2016Publication date: December 13, 2018Applicants: SUNARROW LTD, Niigata UniversityInventors: Yutaka Kuwabara, Atsushi Ogawa, Ken-ichi Mizuno, Hiroki Sato, Shuji Terai
-
Patent number: 9902979Abstract: Provided is a method for producing ambrein, comprising reacting tetraprenyl-?-curcumene cyclase with 3-deoxyachilleol A to obtain ambrein.Type: GrantFiled: August 12, 2014Date of Patent: February 27, 2018Assignee: Niigata UniversityInventors: Tsutomu Sato, Daijiro Ueda, Tsutomu Hoshino